Download Files:

Crolibulin

$200$1,300

Products Details

Product Description

– Crolibulin (EPC2407) is a tubulin polymerization inhibitor, with potent apoptosis induction and cell growth inhibition. Crolibulin has anti-tumor activity. Crolibulin also has cardiovascular toxicity and neurotoxicity[1][2][3].

Web ID

– HY-13603

Storage Temperature

– -20°C, 3 years; 4°C, 2 years (Powder)

Shipping

– Room Temperature

Applications

– Cancer-programmed cell death

Molecular Formula

– C18H17BrN4O3

References

– [1]S. P. Anthony, et al. EPC2407, a new beta-tubulin vascular disrupting agent with potent apoptosis and cell growth inhibition. Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007) 14043-14043.|[2]Kalmuk J, et al. Multimodal imaging guided preclinical trials of vascular targeting in prostate cancer. Oncotarget. 2015 Sep 15;6(27):24376-92.|[3]Zhai X, et al. Discovery and Optimization of Novel 5-Indolyl-7-arylimidazo[1,2-a]pyridine-8-carbonitrile Derivatives as Potent Antitubulin Agents Targeting Colchicine-binding Site. Sci Rep. 2017 Feb 27;7:43398.

CAS Number

– 1000852-17-4

Molecular Weight

– 417.26

Compound Purity

– 98.99

SMILES

– N#CC1=C(N)OC2=C(N)C(N)=CC=C2[C@H]1C3=CC(OC)=C(OC)C(Br)=C3

Clinical Information

– Phase 2

Research Area

– Cancer

Solubility

– DMSO : 125 mg/mL (ultrasonic;warming)

Target

– Apoptosis;Microtubule/Tubulin

Pathway

– Apoptosis;Cell Cycle/DNA Damage;Cytoskeleton

Product type

– Reference compound

Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.